Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01008 vs Bevacizumab in Advanced Nonsquamous NSCLC
NCT03533127Phase 3Unknown
- Sponsor
- Luye Pharma Group
- Start
- Nov 2017
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab MB02 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Best Objective Response Rate at 19 weeks. Status: unknown.
02
Drugs
bevacizumab MB02
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03533127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533127.